Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6114319 | SANDOZ | Compositions containing difluprednate |
May, 2019
(5 years ago) | |
US6114319 (Pediatric) | SANDOZ | Compositions containing difluprednate |
Nov, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-26) | Jun 13, 2019 |
Orphan Drug Exclusivity(ODE) | Jun 13, 2019 |
M(M-127) | Mar 22, 2016 |
New Chemical Entity Exclusivity(NCE) | Jun 23, 2013 |
Pediatric Exclusivity(PED) | Sep 22, 2016 |
New Indication(I-653) | Jun 13, 2015 |
NCE-1 date: 23 September, 2015
Market Authorisation Date: 23 June, 2008
Treatment: NA
Dosage: EMULSION;OPHTHALMIC